XEN gel stent ® in the management of glaucoma: preliminary results of a tertiary center
DOI:
https://doi.org/10.31288/oftalmolzh20231913Keywords:
XEN ® gel stent, XEN45 ® gel stent, glaucomaAbstract
Purpose: To analyze the efficacy and safety of a MIGS device (XEN gel stent ®) in the management of glaucoma in our tertiary center.
Methods: Retrospective analysis of patients submitted to XEN ® implant alone or combined with cataract surgery. Patients with previous filtering surgeries were included. Intraocular pressure (IOP) was evaluated at 1st week, 1st, 3rd, 6th and 12th months after surgery. BCVA, RNFL thickness and number of antiglaucoma medications were evaluated 1 year after surgery. Early and late complications and need for an additional glaucoma surgery were recorded.
Results: Thirty-four eyes from 28 patients were included. The main diagnosis was primary open angle glaucoma (POAG) (58.8%).
IOP decreased from 20.5±4.9 mmHg to 15.4±4.1 mmHg 1 year after surgery (p<0.001). There was also a decrease in the number of antiglaucoma medications, from 3.6±0.6 to 0.6±0.7 (p<0.001). BCVA increased from 0.57±0.30 to 0.87±0.18 in the combined surgery group (p=0.03). RNFL thickness remained stable (p=0.558).
Hypotony occurred in 2 eyes (5.9%). Two eyes (5.9%) needed another glaucoma surgery in the 1st year of follow-up.
Conclusion: According to our results, XEN® alone or combined with phacoemulsification showed to be effective in IOP reduction, with few complications, as a primary surgery or even in eyes with previous filtering surgeries.
References
Buffault J, Baudouin C, Labbé A. XEN® Gel Stent for management of chronic open angle glaucoma: A review of the literature. Journal Français d'Ophtalmologie.2019. Feb; 42(2): e37-e46. https://doi.org/10.1016/j.jfo.2018.12.002
Kalina AG, Kalina PH, Brown MM. XEN® Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United States. Ophthalmology and Therapy, 2019 Sep;8(3):435-446. https://doi.org/10.1007/s40123-019-0192-8
Fea, AM, Durr GM, MaroloP, Malinverni L, Economou MA, Ahmed I. XEN® Gel Stent: A Comprehensive Review on Its Use as a Treatment Option for Refractory Glaucoma. Clinical ophthalmology (Auckland, N.Z.) 2020.14, 1805-1832. https://doi.org/10.2147/OPTH.S178348
Theillac V, Blumen-Ohana E, Akesbi J, Hamard P, Sellam A, Brasnu E. et al. Cataract and glaucoma combined surgery: XEN® gel stent versus nonpenetrating deep sclerectomy, a pilot study. BMC Ophthalmology. 2020; 20(1), 231. https://doi.org/10.1186/s12886-020-01492-z
Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM, Virgili G. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PLOS ONE. 2017. 12(8), e0183142. https://doi.org/10.1371/journal.pone.0183142
Sandhu S, Dorey MW. Case report: Xen ab interno gel stent use in a refractory glaucoma patient with previous filtration surgeries. J Glaucoma. 2018;27(3):e59-e60. https://doi.org/10.1097/IJG.0000000000000864
Ferreira NP, Pinto JM, Teixeira F, Pinto LA. XEN Gel Stent Early Failure-dye-enhanced Ab-externo Revision. Journal of current glaucoma practice. 2018; 12(3), 139-141. https://doi.org/10.5005/jp-journals-10078-1237
Stoner AM, Capitena Young CE, SooHoo JR, Pantcheva MB, Patnaik JL, Kahook MY, Seibold LK. A Comparison of Clinical Outcomes After XEN Gel Stent and EX-PRESS Glaucoma Drainage Device Implantation. J Glaucoma. 2021 Jun 1;30(6):481-488. https://doi.org/10.1097/IJG.0000000000001823
Wagner FM, Schuster AK, Emmerich J, Chronopoulos P, Hoffmann EM. Efficacy and safety of XEN®-Implantation vs. trabeculectomy: Data of a "real-world" setting. PLoS One. 2020 Apr 20;15(4):e0231614. https://doi.org/10.1371/journal.pone.0231614
Theilig T, Rehak M, Busch C, Bormann C, Schargus M, Unterlauft JD. Comparing the efficacy of trabeculectomy and XEN gel microstent implantation for the treatment of primary open-angle glaucoma: a retrospective monocentric comparative cohort study. Scientific reports. 2020., 10(1), 19337. https://doi.org/10.1038/s41598-020-76551-y
Marcos Parra MT, Salinas López JA, López Grau NS, Ceausescu AM, Pérez Santonja JJ. XEN implant device versus trabeculectomy, either alone or in combination with phacoemulsification, in open-angle glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1741-1750. https://doi.org/10.1007/s00417-019-04341-y
Wang B, Leng X, An X, Zhang X, Liu X, Lu X. XEN gel implant with or without phacoemulsification for glaucoma: a systematic review and meta-analysis. Annals of translational medicine. 2020; 8(20), 1309. https://doi.org/10.21037/atm-20-6354
Ibáñez-Muñoz A, Soto-Biforcos VS, Rodríguez-Vicente L, Ortega-Renedo I, Chacón-González M, Rúa-Galisteo O. et al XEN implant in primary and secondary open-angle glaucoma: A 12-month retrospective study. European Journal of Ophthalmology. 2020 Sep;30(5):1034-1041. https://doi.org/10.1177/1120672119845226
Prum BE, Jr., Rosenberg LF, Gedde SJ, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern(®) Guidelines. Ophthalmology 2016;123:P41-p111. https://doi.org/10.1016/j.ophtha.2015.10.053
Marques RE, Ferreira NP, Sousa DC, Pinto J, Barata A, Sens P, Abegão Pinto L. Glaucoma Gel Implant Learning Curve in a Teaching Tertiary Hospital. J Glaucoma. 2019 Jan;28(1):56-60. https://doi.org/10.1097/IJG.0000000000001107
Karimi A, Lindfield D, Turnbull A, Dimitriou C, Bhatia B, Radwan M. et al. A multi-centre interventional case series of 259 ab-interno Xen gel implants for glaucoma, with and without combined cataract surgery. Eye (Lond). 2019 Mar;33(3):469-477. https://doi.org/10.1038/s41433-018-0243-8
Heidinger A, Schwab Ch, Lindner E, Riedl R, Mossböck G. Retrospective Study of 199 Xen45 Stent Implantations From 2014 to 2016. Journal of Glaucoma. 2019; 28(1), 75-79. https://doi.org/10.1097/IJG.0000000000001122
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rita Vieira, Ana Figueiredo, Rita Reis, Isabel Sampaio, Maria João Menéres.
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
